A FA é a arritmia cardíaca sustentada mais comum em adultos em todo o mundo.[1]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.
https://academic.oup.com/eurheartj/article/42/5/373/5899003
http://www.ncbi.nlm.nih.gov/pubmed/32860505?tool=bestpractice.com
Estima-se que a prevalência seja de 2% a 4%.[1]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.
https://academic.oup.com/eurheartj/article/42/5/373/5899003
http://www.ncbi.nlm.nih.gov/pubmed/32860505?tool=bestpractice.com
As estimativas sugerem que a prevalência está aumentando, em parte devido à maior longevidade da população em geral e aos esforços contínuos para detectar a FA não diagnosticada.[1]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.
https://academic.oup.com/eurheartj/article/42/5/373/5899003
http://www.ncbi.nlm.nih.gov/pubmed/32860505?tool=bestpractice.com
[3]National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. June 2021 [internet publication].
https://www.nice.org.uk/guidance/ng196
Se não for tratada, a FA é um fator de risco significativo para AVC, outras morbidades e mortalidade.[1]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.
https://academic.oup.com/eurheartj/article/42/5/373/5899003
http://www.ncbi.nlm.nih.gov/pubmed/32860505?tool=bestpractice.com
Os homens são mais comumente afetados do que as mulheres, e a prevalência aumenta com a idade.[1]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.
https://academic.oup.com/eurheartj/article/42/5/373/5899003
http://www.ncbi.nlm.nih.gov/pubmed/32860505?tool=bestpractice.com
[3]National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. June 2021 [internet publication].
https://www.nice.org.uk/guidance/ng196
[4]Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018 Apr 26;361:k1453.
https://www.bmj.com/content/361/bmj.k1453.long
http://www.ncbi.nlm.nih.gov/pubmed/29699974?tool=bestpractice.com
[5]Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE consortium (biomarker for cardiovascular risk assessment in Europe). Circulation. 2017 Oct 24;136(17):1588-97.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657474
http://www.ncbi.nlm.nih.gov/pubmed/29038167?tool=bestpractice.com
O risco ao longo da vida é estimado em 1 em cada 3 indivíduos de ascendência europeia na idade inicial de 55 anos.[1]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.
https://academic.oup.com/eurheartj/article/42/5/373/5899003
http://www.ncbi.nlm.nih.gov/pubmed/32860505?tool=bestpractice.com
[4]Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018 Apr 26;361:k1453.
https://www.bmj.com/content/361/bmj.k1453.long
http://www.ncbi.nlm.nih.gov/pubmed/29699974?tool=bestpractice.com
[5]Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE consortium (biomarker for cardiovascular risk assessment in Europe). Circulation. 2017 Oct 24;136(17):1588-97.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657474
http://www.ncbi.nlm.nih.gov/pubmed/29038167?tool=bestpractice.com